ALNY Alnylam Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALNY

Price (delayed)

$234.84

Market cap

$29.71B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.64

Enterprise value

$30.32B

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is ...

Highlights
The gross profit has soared by 76% YoY and by 11% from the previous quarter
The company's revenue has surged by 75% YoY and by 10% QoQ
The company's quick ratio fell by 16% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.alnylam.com/
Peers: ARWR REGN SRPT OPK

Key stats

What are the main financial stats of ALNY
Market
Shares outstanding
126.49M
Market cap
$29.71B
Enterprise value
$30.32B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
14.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.14
Earnings
Revenue
$2B
EBIT
-$197.22M
EBITDA
-$100.79M
Free cash flow
$127.82M
Per share
EPS
-$2.64
Free cash flow per share
$1.01
Book value per share
-$1.74
Revenue per share
$15.88
TBVPS
$30.32
Balance sheet
Total assets
$3.82B
Total liabilities
$4.04B
Debt
$1.3B
Equity
-$219.27M
Working capital
$2.05B
Liquidity
Debt to equity
-5.93
Current ratio
3.17
Quick ratio
2.86
Net debt/EBITDA
-6.15
Margins
EBITDA margin
-5%
Gross margin
84%
Net margin
-16.6%
Operating margin
-8.8%
Efficiency
Return on assets
-8.9%
Return on equity
N/A
Return on invested capital
-5.9%
Return on capital employed
-6.8%
Return on sales
-9.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
-1.28%
1 week
-1.26%
1 month
-4.21%
1 year
20.47%
YTD
22.69%
QTD
-3.36%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$2B
Gross profit
$1.68B
Operating income
-$175.8M
Net income
-$332.08M
Gross margin
84%
Net margin
-16.6%
The company's operating margin has surged by 87% YoY and by 43% QoQ
The net margin has soared by 82% YoY and by 31% from the previous quarter
Alnylam Pharmaceuticals's operating income has surged by 78% YoY and by 38% QoQ
The gross profit has soared by 76% YoY and by 11% from the previous quarter

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
14.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.14
ALNY's EPS has surged by 70% year-on-year and by 25% since the previous quarter
The equity has grown by 15% YoY
The company's revenue has surged by 75% YoY and by 10% QoQ
ALNY's price to sales (P/S) is 50% lower than its 5-year quarterly average of 29.3 but 9% higher than its last 4 quarters average of 13.6

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
ALNY's return on sales has surged by 88% year-on-year and by 43% since the previous quarter
ALNY's return on invested capital has surged by 80% year-on-year and by 38% since the previous quarter
The return on assets has surged by 71% year-on-year and by 27% since the previous quarter

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 5% less than the total liabilities
The company's quick ratio fell by 16% YoY
Alnylam Pharmaceuticals's current ratio has decreased by 16% YoY but it has increased by 2.9% from the previous quarter
Alnylam Pharmaceuticals's debt to equity has decreased by 17% YoY
The equity has grown by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.